Cerus Corporation
Cerus Corporation
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs | Hemic and Lymphatic Diseases, Hemolytic Transfusion Reaction, Transfusion Reaction, hematologic disorder, immune system disorder | Not yet recruiting | Phase 2 | 2026-09-22 | NCT07152379 | |
| A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1 | Healthy Subjects | Recruiting | Phase 2 | 2026-09-21 | NCT07015437 | |
| Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Hemorrhagic, blood coagulation disease, coagulation protein disease, congenital afibrinogenemia, hematologic disorder, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, injury | Not yet recruiting | Not stated | 2026-06-17 | NCT07218185 |